Covance is the only contract research organization that can deliver solutions from discovery to commercialization.
Virtual Clinic Tour
Take a look at our cGMP Pharmacy in Dallas
Game-changing control over Phase I drug manufacturing timelines and costs. Tour our Dallas Clinical Research Unit.
Are your economic models delivering?
Transform economic models into highly engaging communication tools.
What matters to investigators
Recent study shows lab preferences make a difference in trial participation.
Solutions to minimize risk and optimize your trial designs
Discover how our innovation, commitment and expertise can accelerate your complex immuno-oncology drug development
Early Phase Development Solutions
Want to reduce your early development timeline by 30%?
Find out how from Pete Sausen, PhD, vice president, early phase development solutions
End-to-end drug & diagnostic development support for a new immuno-oncology agent
Find out how Covance/LabCorp helped a prominent pharmaceutical company enable a faster, more effective launch of their immuno-oncology drug.
SpecimINSIGHTTM Case Study
Actionable consent data leads to no-go decision in five days before initiating costly Phase III trials, saving client an estimated $100M.
When a potentially market-limiting severe adverse reaction appeared in Phase I and II trials for an early stage Alzheimer’s disease drug development program, the client was able to quickly ensure consent for additional testing to properly determine genetic association. This actionable insight also prompted the client to discontinue trials on the initial compound and pivot to a backup compound.
Advancing healthcare through high-quality nonclinical, clinical and commercialization services.
Rare Disease and Orphan Drugs
Webinar: accelerate complex studies across the globe
A range of individual approaches can be integrated to accelerate your progress of complex rare disease studies across the world. Learn how to address key development challenges.
Assessing drug abuse liability
Key considerations – from early initiation to regulatory and market access – to effectively understand and adapt to the changing landscape of abuse potential.
New FDA labeling regulations are here
The new label is intended to better inform consumers about their choices.
We’re the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®
With precision delivery of the largest volume of drug development data on the planet, we can help you identify new approaches and anticipate tomorrow’s challenges.